CL2016003260A1 - Profármacos de gemcitabina - Google Patents

Profármacos de gemcitabina

Info

Publication number
CL2016003260A1
CL2016003260A1 CL2016003260A CL2016003260A CL2016003260A1 CL 2016003260 A1 CL2016003260 A1 CL 2016003260A1 CL 2016003260 A CL2016003260 A CL 2016003260A CL 2016003260 A CL2016003260 A CL 2016003260A CL 2016003260 A1 CL2016003260 A1 CL 2016003260A1
Authority
CL
Chile
Prior art keywords
gemcitabine
gemcitabine prodrugs
prodrugs
alaninyl
benzoxy
Prior art date
Application number
CL2016003260A
Other languages
English (en)
Inventor
Hugh Griffith
Christopher Mcguigan
Magdalena Slusarczyk
Michaela Serpi
Valentina Ferrari
Original Assignee
Nucana Biomed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53499027&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016003260(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1411253.6A external-priority patent/GB201411253D0/en
Application filed by Nucana Biomed Ltd filed Critical Nucana Biomed Ltd
Publication of CL2016003260A1 publication Critical patent/CL2016003260A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Abstract

<p>Gemcitabina-[fenil(benzoxi-L-alaninil)]-(S/R)-fosfato; formulación farmaceutica y uso en el tratamiento del cancer.</p>
CL2016003260A 2014-06-25 2016-12-20 Profármacos de gemcitabina CL2016003260A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2050MU2014 2014-06-25
GBGB1411253.6A GB201411253D0 (en) 2014-06-25 2014-06-25 Prodrug

Publications (1)

Publication Number Publication Date
CL2016003260A1 true CL2016003260A1 (es) 2017-10-06

Family

ID=53499027

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003260A CL2016003260A1 (es) 2014-06-25 2016-12-20 Profármacos de gemcitabina

Country Status (28)

Country Link
US (2) US10662213B2 (es)
EP (2) EP3757112B1 (es)
JP (2) JP6982957B2 (es)
KR (2) KR102563040B1 (es)
CN (2) CN111214480A (es)
AU (2) AU2015278899B2 (es)
CA (1) CA2945938C (es)
CL (1) CL2016003260A1 (es)
CY (1) CY1123389T1 (es)
DK (1) DK3160978T3 (es)
EA (1) EA034890B1 (es)
ES (2) ES2811268T3 (es)
HR (2) HRP20230584T1 (es)
HU (2) HUE053240T2 (es)
IL (2) IL248642B (es)
LT (1) LT3160978T (es)
ME (1) ME03817B (es)
MX (2) MX2021001140A (es)
MY (1) MY183198A (es)
NZ (2) NZ765508A (es)
PH (1) PH12016502553A1 (es)
PL (1) PL3160978T3 (es)
PT (1) PT3160978T (es)
RS (1) RS60968B1 (es)
SG (2) SG10201907898SA (es)
SI (1) SI3160978T1 (es)
TW (2) TWI758728B (es)
WO (1) WO2015198058A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2725491T3 (es) 2012-11-16 2019-09-24 Univ College Cardiff Consultants Ltd Mezcla de RP/SP gemcitabina-[fenil-(benciloxi-L-alaninil)]-fosfato
MY186584A (en) 2014-06-25 2021-07-28 Nucana Biomed Ltd Formulation comprising a gemcitabine-prodrug
LT3160978T (lt) 2014-06-25 2020-08-25 NuCana plc Gemcitabino provaistai
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN106478753A (zh) * 2015-09-16 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种nuc‑1031单一异构体的制备方法和用途
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CA2994502C (en) 2015-10-05 2023-08-01 NuCana plc Combination therapy comprising nuc-1031 and carboplatin for cancer treatment
SI3386998T1 (sl) 2015-12-11 2022-02-28 NuCana plc Diastereoselektivna sinteza fosfatnih derivatov in predzdravila gemcitabina NUC-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
CN107652342A (zh) * 2016-07-23 2018-02-02 江苏万高药业股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
CN106946960A (zh) * 2017-03-29 2017-07-14 郑州泰基鸿诺医药股份有限公司 一种吉西他滨前药的晶型、制备方法、用途和药物组合物
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
CN110215469B (zh) * 2019-07-08 2021-11-30 绍兴市人民医院 一种治疗胆管癌的药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5827727A (en) 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
EP1045897B1 (en) 1998-01-23 2002-01-30 Newbiotics Inc. Enzyme catalyzed therapeutic agents
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
JP4982019B2 (ja) 1999-07-22 2012-07-25 セルメド オンコロジー （ユーエスエイ）， インコーポレイテッド 酵素によって触媒される治療活性化
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2006081364A2 (en) 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Formulations for injection of catecholic butanes, including ndga compounds, into animals
EP1928475B1 (en) 2005-08-15 2018-05-23 Riboscience LLC Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides
AU2007212271B2 (en) 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
GB0821994D0 (en) 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
CN102348712A (zh) 2009-01-09 2012-02-08 卡迪夫大学学院顾问有限公司 用于治疗病毒感染的鸟苷核苷类化合物的磷酰胺酯衍生物
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
RU2012125350A (ru) 2009-11-20 2013-12-27 Клавис Фарма Аса Парентеральные препараты производных гемцитабина
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
PL3447061T3 (pl) 2011-03-01 2022-01-31 NuCana plc Farmaceutyczna formulacja zawierająca pochodną fosforoamidynianową 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu nowotworu
CN104144677B (zh) 2012-01-20 2016-11-23 阿拉塔纳医疗有限公司 滴眼剂组合物
ES2725491T3 (es) * 2012-11-16 2019-09-24 Univ College Cardiff Consultants Ltd Mezcla de RP/SP gemcitabina-[fenil-(benciloxi-L-alaninil)]-fosfato
GB2517988A (en) * 2013-09-09 2015-03-11 Redx Pharma Ltd Compounds
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
WO2015081133A2 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
MY186584A (en) 2014-06-25 2021-07-28 Nucana Biomed Ltd Formulation comprising a gemcitabine-prodrug
LT3160978T (lt) 2014-06-25 2020-08-25 NuCana plc Gemcitabino provaistai
JP6646663B2 (ja) 2014-07-22 2020-02-14 ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
WO2016181093A1 (en) 2015-05-14 2016-11-17 Nucana Biomed Limited Cancer treatments
CA2994502C (en) 2015-10-05 2023-08-01 NuCana plc Combination therapy comprising nuc-1031 and carboplatin for cancer treatment
SI3386998T1 (sl) 2015-12-11 2022-02-28 NuCana plc Diastereoselektivna sinteza fosfatnih derivatov in predzdravila gemcitabina NUC-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
PT3393478T (pt) 2015-12-23 2020-03-24 NuCana plc Terapia combinada
US20190381084A1 (en) 2015-12-23 2019-12-19 Nucana Biomed Limited Combination therapy

Also Published As

Publication number Publication date
AU2015278899B2 (en) 2019-07-18
HRP20230584T1 (hr) 2023-09-15
EA201692312A1 (ru) 2017-04-28
TW201613614A (en) 2016-04-16
TWI695718B (zh) 2020-06-11
KR102563040B1 (ko) 2023-08-02
JP2017519014A (ja) 2017-07-13
CN106459129B (zh) 2020-03-31
HRP20201264T1 (hr) 2021-02-05
US11629164B2 (en) 2023-04-18
CA2945938A1 (en) 2015-12-30
KR20220080220A (ko) 2022-06-14
AU2019216626A1 (en) 2019-09-05
EP3757112B1 (en) 2023-06-07
EP3757112C0 (en) 2023-06-07
KR20170043479A (ko) 2017-04-21
AU2019216626B2 (en) 2020-07-23
MY183198A (en) 2021-02-18
PT3160978T (pt) 2020-08-24
MX2016015628A (es) 2017-07-04
PH12016502553B1 (en) 2017-04-10
JP2020152725A (ja) 2020-09-24
US20200262861A1 (en) 2020-08-20
ES2948660T3 (es) 2023-09-15
US10662213B2 (en) 2020-05-26
NZ725205A (en) 2023-12-22
HUE062474T2 (hu) 2023-11-28
CN111214480A (zh) 2020-06-02
EA034890B1 (ru) 2020-04-02
SG10201907898SA (en) 2019-09-27
RS60968B1 (sr) 2020-11-30
CN106459129A (zh) 2017-02-22
HUE053240T2 (hu) 2021-06-28
LT3160978T (lt) 2020-08-25
MX2021001140A (es) 2022-04-21
IL248642B (en) 2020-03-31
PH12016502553A1 (en) 2017-04-10
JP6970236B2 (ja) 2021-11-24
NZ765508A (en) 2023-12-22
TWI758728B (zh) 2022-03-21
KR102407935B1 (ko) 2022-06-10
IL272724B (en) 2021-06-30
JP6982957B2 (ja) 2021-12-17
SI3160978T1 (sl) 2020-11-30
ES2811268T3 (es) 2021-03-11
WO2015198058A1 (en) 2015-12-30
CA2945938C (en) 2023-04-18
SG11201608808TA (en) 2016-11-29
IL248642A0 (en) 2017-01-31
EP3757112A1 (en) 2020-12-30
DK3160978T3 (da) 2020-08-17
EP3160978A1 (en) 2017-05-03
PL3160978T3 (pl) 2020-11-30
US20170107246A1 (en) 2017-04-20
CY1123389T1 (el) 2021-12-31
TW202033204A (zh) 2020-09-16
AU2015278899A1 (en) 2016-11-03
ME03817B (me) 2021-04-20
IL272724A (en) 2020-04-30
EP3160978B1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
CL2016003260A1 (es) Profármacos de gemcitabina
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
ECSP15026557A (es) Compuestos y sus métodos de empleo
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
ECSP17073743A (es) Moduladores de k-ras
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
CL2016000106A1 (es) Sulfonamidas como moduladores de canales de sodio.
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
CL2015002897A1 (es) Inhibidores de bace1
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
DK3380086T3 (da) Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
BR112016027043A2 (pt) Combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη